Real-world comparative outcomes of pyrotinib-based versus pertuzumab-based first-line therapy in HER2-Positive advanced breast cancer: a multicenter retrospective cohort study from Xinjiang, China.

Yimuran Hujiahemaiti, Yinping Ge, Chao Zhang, Gulisire Abdoukerim, Jing Fei, Ruifeng Qi, Yan Li, Xiaoping Ma, Zhenhui Zhao, Li Li, Dan Liu, Bingyu Li, Xiner Zhang, Bing Zhao

DOI: 10.3389/fphar.2026.1943895

На странице источника доступны аннотация, полный текст или сведения о том, где его прочитать.